Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2

Diabetes Care

Volumn 28, Issue 5, 2005, Pages 1092-1100

  DeFronzo, Ralph A ^a   Ratner, Robert E ^b   Han, Jenny ^c   Kim, Dennis D ^c   Fineman, Mark S ^c   Baron, Alain D ^c  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b MEDSTAR RESEARCH INSTITUTE   (United States)

^c AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PLACEBO;

ADULT; AGED; ARTICLE; BACKACHE; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SELF ADMINISTRATION; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; LIVER DISEASE; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINUSITIS; TREATMENT FAILURE; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; PEPTIDES; PROINSULIN; VENOMS;

EID: 18144401971     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.5.1092     Document Type: Article

References (36)

1. Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787-794, 1999
2. UK Prospective Diabetes Study Group: UK Prospective Diabetes Study 16: Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44:1249-1258, 1995
3. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in subjects with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
4. Koro CM, Bowlin SJ, Bourgeois N, Fedder DO: Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes. Diabetes Care 27:17-20, 2004
5. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS: Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 22:403-408, 1999
6. Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287:360-372, 2002
7. DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131:281-303, 1999
8. DeFronzo RA, Goodman AM: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541-549, 1995
9. Kirpichnikov D, McFarlane SI, Sowers JR: Metformin: an update. Ann Intern Med 137:25-33, 2002
10. Nathan DM: Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 347:1342-1348, 2002
11. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD: Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88:3082-3089, 2003
12. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD: Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26:2370-2377, 2003
13. Nielsen LL, Baron AD: Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. Curr Opinion Investig Drugs 4:401-405, 2003
14. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M: Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48:1026-1034, 1999
15. Parkes DG, Pittner R, Jodka C, Smith P, Young A: Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 50:583-589, 2001
16. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, Bloom SR: Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281:E155-E161, 2001
17. Nielsen LL, Young AA, Parkes D: Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 117:77-88, 2004
18. Egan JM, Clocquet AR, Elahi D: The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 87:1282-1290, 2002
19. Holst JJ: Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 18: 430-441, 2002
20. Holst JJ, Gromada J: Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 287:E199-E206, 2004
21. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-38 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744, 1993
22. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830, 2002
23. Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Göke B: Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J Biol Chem 268:19650-19655, 1993
24. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RGS, Greig NH, Egan JM: Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141:1936-1941, 2000
25. Gedulin BR, Nikoulina SE, Smith PA, Gedulin G, Nielsen LL, Baron AD, Parkes D, Young AA: Exenatide (exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 146:2069-2076, 2005
26. Declaration of Helsinski: Recommendations guiding medical physicians in biomedical research involving human subjects. JAMA 277:925-926, 1997
27. Fineman MS, Shen LZ, Kristin Taylor T, Kim DD, Baron AD: Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side-effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 20:411-417, 2004
28. Neter J, Wasserman W, Kutner MH: Applied Linear Statistical Models. 3rd ed. Momewood, IL, Irwin, 1990
29. Milliken GA, Johnson DE: Analyses of Messy Data. Vol I. Designed Experiments. New York, Van Nostrand Reinhold, 1984
30. Hayter AJ: The maximum familywise error rate of Fisher's least significant difference test. J Am Stat Assoc 396:1000-1004, 1986
31. Davis JE, McDonald JM, Jarret L: A high performance liquid chromatogaraphy method for hemoglobin A1c. Diabetes 27:102-107, 1978
32. Cole RA, Soeldner JS, Dunn PJ, Bunn HF: A rapid method for the determination of glycosylated hemoglobins using high pressure liquid chromatography. Metabolism 27:289-301, 1978
33. Fonseca V, Rosenstock J, Patwardhan R, Salzman A: Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 13:1695-1702, 2000
34. Rendell MS, Glazer NB, Ye Z: Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with type 2 diabetes: influence of prior antidiabetic drug regimen. J Diabetes Complications 17:211-217, 2003
35. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD: Effects of Exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27:2628-2635, 2004
36. Kendall DM, Riddle MC, Zhuang D, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic coń trol and weight in patients with type 2 diabetes treated with metformin and a sulfonylurea. Late-breaking abstract pré sented at the 64th Annual Meeting of the American Diabetes Association, 4-8 June 2004, at the Orange County Convention Center, Orlando, Florida